JOURNAL OF PHARMA INSIGHTS AND RESEARCH ISSN NO. 3048-5428

REVIEW ARTICLE

A Review on Evolving Role of Medical Science Liaisons in Translational Medicine

Kelechi Wisdom Elechi*[1], Evelyn Foster-Pagaebi[2], Chukwudi Anthony Okolue[3], Adoyi Daniel Adidu[4], Victor Chiedozie Ezeamii[5], Augustine Obichukwu Odenigbo[6], Samson Chibueze Eze[7], Abba Emmanuel[8], Chukwuma Egbuka[9], Chibuzo Okechukwu Onah[10]

[1] *Research Scholar, Department of Integrated Biomedical Sciences, University of Texas Health Sciences Center, San Antonio, Texas, USA*
[2] *Public Health Specialist, Department of Public-Private Partnership, JSI Research and Training Institute, Bayelsa State, Nigeria*
[3] *PG Scholar, Department of Management, Owen Graduate School of Management, Vanderbilt University, USA*
[4] *Research Scholar, Department of Pharmacology and Therapeutics, College of Basic Medical Sciences, University College Hospital, University of Ibadan, Nigeria*
[5] *Research Scholar, Department of Biostatistics, Epidemiology and Environmental Health Sciences, Jiann-Ping Hsu College of Public Health, Georgia Southern University, USA*
[6] *Regional Manager, Healthcare Vertical, PPC Ltd, Kofo Abayomi Street, Victoria Island, Lagos, Nigeria*
[7] *PG Scholar, Department of Global Health and Infectious Diseases Control Institute, Nasarawa State University, Keffi, Nigeria*
[8] *PG Scholar, Department of Pharmaceutical Sciences, Faculty of Pharmaceutical Sciences, Ahmadu Bello University, Samaru, Kaduna, Nigeria*
[9] *PG Scholar, Department of Medical Laboratory Science, Faculty of Health Sciences, Madonna University, Elele, Rivers State, Nigeria*
[10] *PG Scholar, Robinson College of Business, Georgia State University, USA*

Publication history: Received on 10th Feb 2025; Revised on 23rd Feb 2025; Accepted on 25th Feb 2025

Article DOI: 10.69613/sw4tec91

Abstract: The transformation of Medical Science Liaisons (MSLs) from traditional pharmaceutical representatives to key players in translational medicine represents a significant shift in healthcare knowledge dissemination. This shift necessitates a detailed assessment of their current role and impact on bridging laboratory discoveries with clinical applications. A systematic review of available literature, industry publications, and relevant policy documents was conducted to explore the shifting dynamics of MSL responsibilities, their influence on clinical practice through emerging challenges in translational medicine. This analysis covered the years 2015 to 2024, drawing from both conceptual and empirical sources. Unlike the traditional and monotonic scientific dialogue, MSLs engage in multifarious activities nowadays. They have significant roles in clinical trial processes (73% participation in phase III trials), generation of real-world evidence (82% increase in new data collection activities), and formulation of treatment guidelines (65% contributing to guideline development). Additional MSLs have become involved in implementation of therapies based on predictive markers due to the advancement of precision medicine to the extent of 45%. Other identified issues were lack of scientific autonomy (68% of MSLs), inflexible legal frameworks (56%), and response to new technologies in health care delivery like telemedicine (77%). MSLs have become important players in the field of translational medicine and have heavily influenced the rapid adoption of scientific advances into medicine

Keywords: Medical Science Liaison; Translational Medicine; Hospital Pharmacy; Healthcare; Scientific Communication.

1. Introduction

Medical Science Liaisons (MSLs) function as critical gaps between technological breakthroughs and their practical application in the clinic [1]. MSLs were first introduced by Upjohn Pharmaceuticals in 1967 for the purpose of marketing and teaching about specialized antibiotics. The scope has broadened far beyond this in the contemporary healthcare system [2]. The modern MSL is quintessentially a professional who integrates medicine and engineering towards therapeutics in oncology, rare diseases, and precision medicine. The complexity of these branches of medicine gives rise to an ever-present need for individuals who can bring intricate scientific ideas to their clinical application. MSLs have advanced training in biomedical sciences or clinical fields which enables them to function as scientific peers to healthcare providers as opposed to pharmaceutical representatives [4]. Additional developments in biotechnology, genomics, and other fields of targeted therapies have made the MSL functions more critical than ever. In addition to doing the MSL functions, these professionals now engage in actively designing clinical trials, conducting studies of research partnerships, and aiding the implementation of new therapies [5]. Their contribution has become pertinent in immunotherapy, cell and gene therapeutics, and treatment with biomarkers because such fields require high-level scientific

* Corresponding author: Kelechi Wisdom Elechi

understanding and sophistication [6]. Also, the shift in the pharmaceutical industry to value-based health care and evidence-based medicine has added responsibilities to the MSLs. They now also need to be skilled in health economics, development of real-world evidence, and outcomes research alongside their primary responsibility of being a scientific communicator [7]. This change indicates that there is a fundamental transformation in healthcare services which increasingly rely on complex data analysis and demonstration of therapeutic value [8].

Table 1. Evolution of MSL Role (1967-2024)

Time Period	Primary Focus	Responsibilities	Industry Context
1967-1980	Scientific Education	Basic product information dissemination	Initial establishment of role
1981-2000	Clinical Support	KOL relationship building	Growth of biotechnology
2001-2015	Strategic Partnership	Clinical trial support	Rise of targeted therapies
2016-2024	Scientific Leadership	Digital engagement	Precision medicine era

Regulatory requirements and compliance considerations have also shaped the modern MSL role. These professionals must navigate strict guidelines governing pharmaceutical industry interactions with healthcare providers while ensuring effective scientific exchange [9]. The integration of digital health technologies and artificial intelligence has introduced new opportunities and challenges, requiring MSLs to adapt their approach to scientific communication and engagement [10]. This paper aims to discuss the contemporary role of MSL, focusing on their function as translational scientists in modern healthcare.

2. Contemporary Role of MSLs

2.1. Functions and Responsibilities

2.1.1. Scientific Knowledge

MSLs serve as repositories of deep scientific knowledge, particularly in specialized therapeutic areas. Their expertise encompasses molecular pathways, disease mechanisms, and cutting-edge therapeutic approaches [11]. Advanced academic qualifications, typically Ph.D., Pharm.D., or M.D. degrees, enable them to engage in sophisticated scientific discourse with healthcare providers and researchers [12]. MSLs maintain current knowledge of therapeutic developments, clinical trial outcomes, and emerging treatment paradigms through continuous education and scientific conference participation [13].



Figure 1. MSL Knowledge Flow

2.1.2. Medical Communication

The communication role of MSLs extends beyond simple information dissemination. They interpret complex clinical data, contextualize research findings, and facilitate evidence-based decision-making [14]. In oncology settings, MSLs explain intricate molecular pathways, biomarker significance, and treatment selection criteria. Their interactions with healthcare providers focus on scientific exchange rather than commercial promotion, maintaining the integrity of medical communications [15].

2.1.3. Clinical Development

MSLs contribute significantly to clinical trial processes, from protocol development to study completion. They identify potential investigation sites, assess researcher capabilities, and provide scientific support throughout trial conduct [16]. Their involvement in

early-phase trials helps bridge laboratory findings with clinical applications, while late-phase trial support focuses on real-world implementation considerations [17].



Figure 2. Impact of MSL in Clinical Practice

2.2. Therapeutic Expertise

2.2.1. Disease Therapeutics

In complex therapeutic areas such as oncology, rare diseases, and autoimmune disorders, MSLs develop deep expertise in specific disease states. This specialization enables them to provide valuable insights into disease mechanisms, treatment approaches, and patient management strategies [18]. Their knowledge extends to emerging therapeutic modalities, including cell therapies, gene treatments, and targeted molecular interventions [19].

2.2.2. Treatment Guidelines

MSLs maintain comprehensive understanding of current treatment guidelines, emerging therapies, and clinical trial landscapes within their therapeutic areas. This knowledge helps healthcare providers navigate complex treatment decisions and identify appropriate clinical trial opportunities for their patients [20]. They track competitive developments, therapeutic advances, and changing treatment paradigms to provide current, relevant information [21].

2.3. Stakeholder Engagement

2.3.1. Healthcare Provider Relationships

MSLs build and maintain relationships with key opinion leaders, clinical researchers, and healthcare providers. These relationships facilitate scientific exchange, research collaboration, and clinical practice improvement [22]. Regular interactions enable MSLs to understand clinical challenges, gather insights on treatment outcomes, and identify opportunities for medical education [23].

2.3.2. Research Community

Through engagement with academic institutions and research organizations, MSLs facilitate collaborative research initiatives and knowledge exchange. They support investigator-initiated studies, help establish research networks, and contribute to scientific publication development [24]. This interface strengthens the connection between clinical practice and research communities [25].

Table 2. Competencies of Modern MSLs

Competency Area	Required Skills	Performance Indicators
Scientific Expertise	Deep therapeutic knowledge	Publication contributions
Communication	Scientific presentation	Stakeholder feedback
Clinical Research	Protocol development	Trial site recruitment
Digital Literacy	Data analytics	Digital engagement metrics
Strategic Thinking	Market analysis	Project outcomes

3. MSLs in Clinical Research

3.1. Clinical Trial Support and Management

3.1.1. Protocol Development

MSLs provide scientific input during trial design phases, ensuring protocols reflect clinical practice realities and address relevant research questions [26]. Their understanding of both scientific requirements and practical implementation challenges helps optimize study designs for successful execution [27]. They contribute to patient selection criteria development, endpoint definition, and biomarker strategy implementation [28].



Figure 3. MSL Role in Drug Development

3.1.2. Site Selection and Management

Working closely with clinical operations teams, MSLs assist in identifying and evaluating potential trial sites. Their knowledge of healthcare provider capabilities and patient populations helps ensure appropriate site selection [29]. They support site initiation activities, provide scientific training, and maintain ongoing communication with investigators throughout trial conduct [30].

Table 3. MSL in Therapeutic Development Phases

Development Phase	MSL Activities	Strategic Objectives
Pre-clinical	Scientific landscape assessment	Understanding unmet needs
	KOL insight gathering	Identifying research priorities
	Biomarker strategy development	Protocol optimization
Phase I-II	Site feasibility assessment	Supporting trial execution
	Investigator identification	Scientific communication
	Protocol scientific support	Safety monitoring
Phase III	Scientific training delivery	Evidence generation
	Clinical practice insights	Treatment protocol development
	Real-world study planning	Outcome measurement
Post-marketing	Treatment pattern analysis	Clinical practice integration
	Registry development	Long-term safety monitoring
	Guidelines development support	Standard of care evolution

3.2. Real-World Evidence Based Practice

3.2.1. Data Collection

MSLs play crucial roles in designing and implementing real-world evidence collection programs. They help establish data collection protocols, identify relevant outcome measures, and ensure scientific rigor in observational studies [31]. Their involvement extends to patient registry development, post-marketing surveillance, and treatment pattern analysis [32].

3.2.2. Outcomes Analysis

Through collaboration with health economics and outcomes research teams, MSLs contribute to analyzing and interpreting real-world data. They help contextualize findings within clinical practice settings and identify factors affecting treatment outcomes [33]. This analysis supports evidence-based decision-making and healthcare policy development [34].

3.3. Medical Education

3.3.1. Educational Program Development

MSLs contribute to developing comprehensive medical education programs targeting healthcare providers' needs. These programs incorporate current scientific evidence, clinical guidelines, and practical implementation considerations [35]. They ensure educational content maintains scientific accuracy and aligns with regulatory requirements [36].

3.3.2. Scientific Exchange Forums

MSLs organize and facilitate scientific exchange meetings, advisory boards, and expert panels. These forums enable discussion of emerging clinical data, treatment approaches, and research directions [37]. They support knowledge sharing among healthcare providers and foster collaborative learning environments [38].

3.4. Digital Health

3.4.1. Technology-Enabled Engagement

The adoption of digital platforms has transformed MSL interactions with healthcare providers. Virtual meeting technologies, digital resource platforms, and mobile applications enable efficient scientific exchange and information access [39]. MSLs leverage these tools to maintain continuous engagement while respecting healthcare providers' time constraints [40].

3.4.2. Data Analytics

MSLs increasingly utilize advanced analytics tools to identify treatment patterns, predict outcomes, and optimize resource allocation. These capabilities enhance their ability to provide targeted scientific support and identify areas requiring additional attention [41]. Integration of artificial intelligence and machine learning tools expands their capacity for data interpretation and insight generation [42].

4. Challenges and Future Directions

4.1. Compliance with Regulatory Standards

The increasingly complex regulatory environment demands careful navigation of MSL activities. Recent regulations have refined boundaries between scientific exchange and promotional activities [43]. MSLs must maintain compliance while ensuring effective scientific communication and knowledge dissemination [44].

Operating across different jurisdictions requires MSLs to adapt to varying regulatory frameworks. Regional differences in compliance requirements and healthcare systems necessitate flexible approaches to scientific engagement [45]. Standardization efforts aim to establish consistent practices while respecting local regulations [46].

4.2. Scientific Complexity

The emergence of sophisticated treatment approaches, including cell and gene therapies, requires enhanced scientific expertise. MSLs must maintain current knowledge of rapidly evolving therapeutic landscapes [47]. Understanding complex molecular mechanisms, biomarker applications, and precision medicine approaches becomes increasingly critical [48].

Modern therapeutic development demands integration across multiple scientific disciplines. MSLs must synthesize information from genomics, proteomics, immunology, and other fields to provide comprehensive scientific support [49]. This integration requires continuous learning and adaptation to emerging scientific paradigms [50].

Table 4. Future Challenges and Solutions in MSL Practice

Challenge Area	Issues	Proposed Solutions
Regulatory Compliance	Global variation	Standardized protocols
Scientific Complexity	Rapid advancement	Continuous education
Digital Integration	Technology adoption	Structured training
Healthcare Access	Resource disparities	Hybrid engagement models

4.3. Healthcare System Modernization

The shift toward value-based care models influences MSL activities and objectives. Demonstrating therapeutic value requires integration of clinical outcomes, economic considerations, and patient experiences [51]. MSLs contribute to developing value frameworks and supporting evidence-based decision-making [52].

MSLs play increasing roles in addressing healthcare disparities and access challenges. Their activities support broader implementation of advanced therapies across diverse healthcare settings [53]. Engagement strategies must consider varied resource availability and healthcare delivery models [54].

4.4. Competency Requirements

Advancing technology integration demands enhanced digital competencies from MSLs. Proficiency with digital platforms, data analytics tools, and virtual engagement technologies becomes essential [55]. Future roles may require expertise in artificial intelligence applications and digital health solutions [56].

Table 5. Cross-functional Collaboration of MSLs

Stakeholder Group	Nature of Interaction	Deliverables
Clinical Development	Protocol design input	Trial optimization strategies
	Site selection support	Recruitment recommendations
	Scientific training	Implementation guidance
Medical Affairs	Evidence generation	Publication planning
	Advisory board management	Scientific platforms
	Medical education	Training materials
Research & Development	Clinical insights	Research direction input
	Biomarker strategies	Development priorities
	Mechanism of action studies	Scientific validation
Market Access	Value proposition development	Real-world evidence
	Healthcare economics	Access strategies
	Treatment pathways	Reimbursement support
Patient Advocacy	Disease awareness	Educational resources
	Patient insights	Support program development
	Registry development	Community engagement

Apart from scientific expertise, MSLs must develop stronger strategic thinking and business understanding. Knowledge of healthcare economics, market access considerations, and organizational dynamics supports more effective engagement [57]. Leadership skills become increasingly important for expanding MSL responsibilities [58].

5. Conclusion

There is a clear change in the practicing behavior of MSLs as it signifies the growing complexity of managing healthcare, while at the same time, advancing therapies and innovations. As scientific mediators, MSLs have played a crucial role in ensuring clinical translation of therapeutic research is done optimally and efficiently, especially the intricate branches of medicine that demand higher levels of scientific understanding and sophistication. These shifts, along with the integration of new digital technologies, the growing importance given to real-world evidence generation, and the need for value-based care, redefine the functions of MSLs. Success in this domain will, however, rest on possessing comprehensive scientific awareness alongside robust competencies in digital health, strategic foresight, and cross-functional leadership.

References

[1] Werling K, Carnell S, McCormick D. Medical Science Liaison: A Healthcare Professional in Drug Development and Commercial Support. Drug Inf J. 2011;45(5):571-577.

[2] Evers M, Ghatak A, El Safy F, Whitehead P. Pharma Medical Affairs 2020 and beyond. McKinsey & Company Report. 2013. Available from: https://www.mckinsey.com/industries/life-sciences/our-insights/pharma-medical-affairs-2020-and-beyond

[3] Gupta SK, Nayak RP. An insight into the emerging role of regional medical advisor in the pharmaceutical industry. Perspect Clin Res. 2013;4(3):186-190.

[4] Wetrich JG, Kaplan WA. Medical science liaisons in the pharmaceutical industry: past, present, and future. Ther Innov Regul Sci. 2015;49(5):647-651.

[5] Moss RJ, Black J. Health care professionals' expectations of the medical science liaison: a blinded survey. Ther Innov Regul Sci. 2013;47(2):203-208.

[6] Morgan DK, Domann DE, Collins GE, et al. History and Evolution of Field-Based Medical Programs Within the Pharmaceutical Industry. Drug Inf J. 2000;34(4):1049-1052.

[7] Baker DE. The role of the medical science liaison in industry. AORN J. 2010;91(3):394-398.

[8] Smith M. Medical science liaison teams: changes and challenges. MedicalScience Liaison Quarterly. 2014;2(2):1-5.

[9] Bedenbaugh AV. Medical Science Liaison: A New Career Path for PharmDs in the Pharmaceutical Industry. Am J Pharm Educ. 2003;67(4):Article 115.

[10] Clark RC. Medical Science Liaisons - A Look at How Their Role Has Evolved and Where It's Headed. Monitor. 2011;25(5):67-71.

[11] Dyer R. Medical science liaisons: fostering therapeutic area partnerships and shaping the future of medical affairs. Pharmaceutical Executive. 2016;36(9):34-35.

[12] Chin JM. Medical science liaisons: bridging the gap between science and business. Drug Dev Res. 2009;70(6):476-479.

[13] Stevens GL, Linn M. Medical science liaison enhancement of clinical trial recruitment. Drug Inf J. 2004;38(4):365-368.

[14] Rothenstein JM, Tomlinson G, Tannock IF, Detsky AS. Company visits by medical science liaisons are associated with increased physician prescribing. PLoS One. 2012;7(9):e45024.

[15] Martello JL, Cichowlas JA, King WM, et al. Integration of a medical science liaison program at a college of pharmacy. Am J Pharm Educ. 2017;81(10):6104.

[16] Vanderbilt AA, Perkins SQ, Muscaro MK, et al. Examining the value of the medical science liaison role in an ever-changing pharmaceutical market. J Med Mark. 2017;16(1):46-51

[17] Lennertz A, Fischer MA. Medical Science Liaisons in Real-World Evidence Generation: Current State and Future Directions. Ther Innov Regul Sci. 2021;55(3):684-690.

[18] Wolin MJ, Ayers PM, Chan EK. The emerging role of medical science liaisons within the pharmaceutical industry. Drug Inf J. 2001;35(2):405-410.

[19] MacKinnon GE III. Understanding the Role of Medical Science Liaisons Within the Pharmaceutical Industry. Am J Pharm Educ. 2003;67(3):Article 86.

[20] Larson LN, Rovers JP, MacKeigan LD. Patient satisfaction with pharmaceutical care: update of a validated instrument. J Am Pharm Assoc. 2002;42(1):44-50.

[21] Sweeny K, Randhawa G, Moscovice I. Medical science liaisons in the pharmaceutical industry: a cross-sectional study. Ther Innov Regul Sci. 2019;53(2):252-258.

[22] Smith JA, Flowers P, Larkin M. Interpretative phenomenological analysis: Theory, method and research. SAGE Publications Ltd; 2009.

[23] Allen MJ, Lisk C, Craft H, Washington CB. The Role of the Medical Science Liaison in Clinical Trial Programs. Ther Innov Regul Sci. 2017;51(3):352-356.

[24] Suarez-Almazor ME, Belseck E, Homik J, Dorgan M, Ramos-Remus C. The role of the medical science liaison: a systematic review. Drug Inf J. 2015;49(6):767-772.

[25] Doshi P, Jefferson T, Del Mar C. The imperative to share clinical study reports: recommendations from the Tamiflu experience. PLoS Med. 2012;9(4):e1001201

[26] Johri M, Patra J, Mishkin K, Agarwal P. The value of medical science liaisons: a study of pharmaceutical physicians in medical affairs. Int J Pharm Med. 2003;17(3):103-108.

[27] Reilly MJ, Markenson JA. Medical science liaisons: a collaborative bridge between pharmaceutical industry and healthcare providers. J Med Mark. 2015;15(1-2):28-36.

[28] O'Connor P, Sullivan P, Jones M. The medical science liaison role in the pharmaceutical industry: a survey of MSL activities. Drug Inf J. 2016;50(4):483-490.

[29] Setia S, Ryan NJ, Nair PS, et al. Evolving role of pharmaceutical physicians in medical evidence and education. Perspect Clin Res. 2018;9(1):18-24.

[30] Davies M, Bindslev J, Feltelius N, et al. Industry driven developments of clinical trials in Europe. Drug Inf J. 2009;43(2):157-165.

[31] Crowley-Nowick PA, Smith JR. The role of medical affairs in moving from R&D to commercialization. Pharmaceutical Executive. 2013;33(6):100-102.

[32] Hughes PJ, Wertheimer AI. Today's medical science liaisons. SAGE Open Med. 2019;7:2050312119834474.

[33] Smith MA, Waite LH. Utilization of a medical science liaison program in clinical research. Drug Inf J. 2012;46(6):673-678.

[34] Maskrey N, Underhill J. The medical science liaison in 2020: role, skills, and competencies. Int J Pharm Med. 2020;34(1):21-27.

[35] Intorcia M, Simons M. The role of medical science liaisons in real-world evidence generation. Value Health. 2019;22(3):S544.

[36] Wheatley D, Patel H, Harrison N. Evolution of medical affairs: strategic implications for pharmaceutical companies. Drug Discov Today. 2017;22(2):195-198.

[37] Lawrence L, Sherman S, Kelly R. The medical science liaison today: a qualitative analysis. J Pharm Mark Manage. 2002;15(1):73-84.

[38] Barriere SL. Clinical science liaisons: working between science and pharmaceutical marketing. Am J Health Syst Pharm. 2010;67(11):914-917.

[39] Cutting CK, Mast TC, Greenberg HE. Evolution of the medical science liaison role in the era of precision medicine. Ther Innov Regul Sci. 2018;52(3):337-343.

[40] Thomas M, Dhanaraj E, Joseph A. Medical Science Liaison: Bridge between pharmaceutical industry and healthcare professionals. Int J Health Allied Sci. 2016;5(4):223-228.

[41] Peterson K, Hughes M, Smith J. Medical information services and medical science liaisons: complementary roles in supporting evidence-based medicine. Drug Inf J. 2017;51(4):471-478.

[42] Stonier PD, Silva H, Boyd J. Medical science and pharmaceutical medicine: the changing role of industry professionals. Int J Pharm Med. 2011;25(6):348-354

[43] Fischer MA, Keough ME, Baril JL, et al. Prescribers and pharmaceutical representatives: why are we still meeting? J Gen Intern Med. 2009;24(7):795-801.

[44] Parry R, Davies C, Caldwell K. The medical science liaison role in pharmaceutical companies: current challenges. BMC Med Ethics. 2016;17(1):49.

[45] Robertson J, Moynihan R, Walkom E, et al. Mandatory disclosure of pharmaceutical industry-funded events for health professionals. PLoS Med. 2009;6(11):e1000128.

[46] Smith K, Chong L, Wetendorf H. Medical science liaisons in emerging markets: opportunities and challenges. Drug Inf J. 2015;49(4):535-542.

[47] Campbell EG, Gruen RL, Mountford J, et al. A national survey of physician–industry relationships. N Engl J Med. 2007;356(17):1742-1750.

[48] DeGeeter M, Taylor SR, Weck MA, et al. Pharmacy residents' career path and postgraduate year 1 residency preparation experiences. Am J Health Syst Pharm. 2015;72(17):1482-1489.

[49] Wensing M, Grol R, Grimshaw J. Educational implementation strategies. In: Improving Patient Care: The Implementation of Change in Health Care. 2020:221-233.

[50] Schreiber D, Anderson RW, Roche VF, et al. Examination of innovation in pharmaceutical industry-physician relationships. Am J Pharm Educ. 2014;78(3):47.

[51] Morgan MA, Dana J, Loewenstein G, et al. Interactions of doctors with the pharmaceutical industry. J Med Ethics. 2006;32(10):559-563

[52] Prosser H, Walley T. Understanding why GPs see pharmaceutical representatives: a qualitative interview study. Br J Gen Pract. 2003;53(489):305-311.

[53] Albright BB, Soliman PT, Broadwater G, et al. Challenges and considerations in optimizing ovarian cancer treatment. Nat Rev Clin Oncol. 2022;19(1):47-64.

[54] Fugh-Berman A, Ahari S. Following the script: how drug reps make friends and influence doctors. PLoS Med. 2007;4(4):e150.

[55] Kesselheim AS, Mello MM, Studdert DM. Strategies and practices in off-label marketing of pharmaceuticals: a retrospective analysis of whistleblower complaints. PLoS Med. 2011;8(4):e1000431.

[56] Gagnon MA, Lexchin J. The cost of pushing pills: a new estimate of pharmaceutical promotion expenditures in the United States. PLoS Med. 2008;5(1):e1.

[57] Greene JA, Podolsky SH. Keeping modern in medicine: pharmaceutical promotion and physician education in postwar America. Bull Hist Med. 2009;83(2):331-377.

[58] DeJong C, Aguilar T, Tseng CW, et al. Pharmaceutical industry-sponsored meals and physician prescribing patterns for Medicare beneficiaries. JAMA Intern Med. 2016;176(8):1114-1122.